These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 17382926)

  • 1. Pharmacological characterisation and inhibitory effects of (2R,3R,4S,5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol, a novel ligand that demonstrates both adenosine A(2A) receptor agonist and adenosine A(3) receptor antagonist activity.
    Bevan N; Butchers PR; Cousins R; Coates J; Edgar EV; Morrison V; Sheehan MJ; Reeves J; Wilson DJ
    Eur J Pharmacol; 2007 Jun; 564(1-3):219-25. PubMed ID: 17382926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of adenosine A2A and A2B receptors in the regulation of TNF-alpha production by human monocytes.
    Zhang JG; Hepburn L; Cruz G; Borman RA; Clark KL
    Biochem Pharmacol; 2005 Mar; 69(6):883-9. PubMed ID: 15748700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression, pharmacological profile, and functional coupling of A2B receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, [3H]MRE 2029-F20.
    Gessi S; Varani K; Merighi S; Cattabriga E; Pancaldi C; Szabadkai Y; Rizzuto R; Klotz KN; Leung E; Mac Lennan S; Baraldi PG; Borea PA
    Mol Pharmacol; 2005 Jun; 67(6):2137-47. PubMed ID: 15788741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding.
    Priego EM; Pérez-Pérez MJ; von Frijtag Drabbe Kuenzel JK; de Vries H; Ijzerman AP; Camarasa MJ; Martín-Santamaría S
    ChemMedChem; 2008 Jan; 3(1):111-9. PubMed ID: 18000937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the A1 adenosine receptor.
    Baraldi PG; Romagnoli R; Pavani MG; Nuñez Mdel C; Tabrizi MA; Shryock JC; Leung E; Moorman AR; Uluoglu C; Iannotta V; Merighi S; Borea PA
    J Med Chem; 2003 Feb; 46(5):794-809. PubMed ID: 12593659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of novel 1-deoxy-1-[6-[((hetero)arylcarbonyl)hydrazino]- 9H-purin-9-yl]-N-ethyl-beta-D-ribofuranuronamide derivatives as useful templates for the development of A2B adenosine receptor agonists.
    Baraldi PG; Preti D; Tabrizi MA; Fruttarolo F; Romagnoli R; Carrion MD; Cara LC; Moorman AR; Varani K; Borea PA
    J Med Chem; 2007 Jan; 50(2):374-80. PubMed ID: 17228880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists.
    Baraldi PG; Preti D; Zaid AN; Saponaro G; Tabrizi MA; Baraldi S; Romagnoli R; Moorman AR; Varani K; Cosconati S; Di Maro S; Marinelli L; Novellino E; Borea PA
    J Med Chem; 2011 Jul; 54(14):5205-20. PubMed ID: 21675777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors.
    van den Nieuwendijk AM; Pietra D; Heitman L; Göblyös A; IJzerman AP
    J Med Chem; 2004 Jan; 47(3):663-72. PubMed ID: 14736246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of novel N6-[4-(substituted)sulfonamidophenylcarbamoyl]adenosine-5'-uronamides as A3 adenosine receptor agonists.
    Baraldi PG; Fruttarolo F; Tabrizi MA; Romagnoli R; Preti D; Bovero A; Pineda de Las Infantas MJ; Moorman A; Varani K; Borea PA
    J Med Chem; 2004 Oct; 47(22):5535-40. PubMed ID: 15481989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
    Varani K; Merighi S; Gessi S; Klotz KN; Leung E; Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Borea PA
    Mol Pharmacol; 2000 May; 57(5):968-75. PubMed ID: 10779381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel partial agonist of the A(1)-adenosine receptor and evidence of receptor homogeneity in adipocytes.
    Fatholahi M; Xiang Y; Wu Y; Li Y; Wu L; Dhalla AK; Belardinelli L; Shryock JC
    J Pharmacol Exp Ther; 2006 May; 317(2):676-84. PubMed ID: 16410404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
    Minetti P; Tinti MO; Carminati P; Castorina M; Di Cesare MA; Di Serio S; Gallo G; Ghirardi O; Giorgi F; Giorgi L; Piersanti G; Bartoccini F; Tarzia G
    J Med Chem; 2005 Nov; 48(22):6887-96. PubMed ID: 16250647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse spinal cord compression injury is reduced by either activation of the adenosine A2A receptor on bone marrow-derived cells or deletion of the A2A receptor on non-bone marrow-derived cells.
    Li Y; Oskouian RJ; Day YJ; Rieger JM; Liu L; Kern JA; Linden J
    Neuroscience; 2006 Sep; 141(4):2029-39. PubMed ID: 16777350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine A1 receptor-mediated inhibition of dopamine release from rat striatal slices is modulated by D1 dopamine receptors.
    O'Neill C; Nolan BJ; Macari A; O'Boyle KM; O'Connor JJ
    Eur J Neurosci; 2007 Dec; 26(12):3421-8. PubMed ID: 18052983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic and functional properties of [3H]ZM241385, a high affinity antagonist for adenosine A2A receptors.
    Uustare A; Vonk A; Terasmaa A; Fuxe K; Rinken A
    Life Sci; 2005 Feb; 76(13):1513-26. PubMed ID: 15680315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioligand binding and functional responses of ligands for human recombinant adenosine A(3) receptors.
    Yates L; Clark JH; Martin TJ; James S; Broadley KJ; Kidd EJ
    Auton Autacoid Pharmacol; 2006 Apr; 26(2):191-200. PubMed ID: 16553647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist.
    Ransom RW; Harrell CM; Reiss DR; Murphy KL; Chang RS; Hess JF; Miller PJ; O'Malley SS; Hey PJ; Kunapuli P; Su DS; Markowitz MK; Wallace MA; Raab CE; Jones AN; Dean DC; Pettibone DJ; Freidinger RM; Bock MG
    Eur J Pharmacol; 2004 Sep; 499(1-2):77-84. PubMed ID: 15363953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of A2A adenosine receptors inhibits expression of alpha 4/beta 1 integrin (very late antigen-4) on stimulated human neutrophils.
    Sullivan GW; Lee DD; Ross WG; DiVietro JA; Lappas CM; Lawrence MB; Linden J
    J Leukoc Biol; 2004 Jan; 75(1):127-34. PubMed ID: 14525968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
    Mihara T; Mihara K; Yarimizu J; Mitani Y; Matsuda R; Yamamoto H; Aoki S; Akahane A; Iwashita A; Matsuoka N
    J Pharmacol Exp Ther; 2007 Nov; 323(2):708-19. PubMed ID: 17684118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.